The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ®, also known as afami-cel) for the treatment of adults with a rare ...
Clearly some STS subtypes are more responsive to certain therapies than others. The differential response to cytotoxic agents stems from mechanisms of oncogenesis and progression diverse for each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback